Resultats de la cerca - Julio Delgado

Refinar resultats
  1. 1
    Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies

    Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies per Julio Delgado, Ferran Nadeu, Dolors Colomer, Elı́as Campo

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Unlocking the potential of engineered immune cell therapy for solid tumors

    Unlocking the potential of engineered immune cell therapy for solid tumors per Víctor Albarrán, Laura Angelats, Julio Delgado, Alena Gros, Álvaro Urbano-Ispízua, Sònia Guedan, Aleix Prat

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies

    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies per Helena Brillembourg, Núria Martínez‐Cibrián, Mireia Bachiller, Letícia Alserawan, Valentín Ortiz‐Maldonado, Sònia Guedan, Julio Delgado

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC

    Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI I... per Pere Barba, José Luís Piñana, Rodrigo Martino, David Valcárcel, Alex Amorós, Anna Sureda, Javier Briones, Julio Delgado, Salut Brunet, Jorge Sierra

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (<scp><i>IGHV</i></scp> mutational status and <scp>FISH</scp> cytogenetics) separates patients with different outcome and simplifies the <scp>CLL‐IPI</scp>

    Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (<scp><i>IGHV</i></scp> mutational status and <scp>FISH</scp> cytogenetics) separates patients with... per Julio Delgado, Michael Doubek, Tycho Baumann, Jana Kotašková, Stefano Molica, Pablo Mozas, Alfredo Rivas‐Delgado, Fortunato Morabito, Šárka Pospı́šilová, Emili Montserrat

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT

    Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT per Rodrigo Martino, José Luís Piñana, Rocío Parody, David Valcárcel, Anna Sureda, Salut Brunet, Javier Briones, Julio Delgado, F Sánchez, Núria Rabella, Jorge Sierra

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

    EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma per Kyriaki Tzogani, Karri Penttilä, Johanna Lähteenvuo, Tuomo Lapveteläinen, Lucía López‐Anglada, Carolina Prieto, Blanca Garcia-Ochoa, Harald Enzmann, Christian Gisselbrecht, Julio Delgado, Francesco Pignatti

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia

    Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia per Neus Giménez, Ralph Schulz, Morihiro Higashi, Marta Aymerich, Neus Villamor, Julio Delgado, Manel Juan, Mònica López‐Guerra, Elı́as Campo, Laia Rosich, Martina Seiffert, Dolors Colomer

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

    Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study per Julio Delgado, Kirsty Thomson, Nigel H. Russell, Joanne Ewing, Wendy A. Stewart, Gordon Cook, Stephen Devereux, Richard Lovell, Rajesh Chopra, David I. Marks, Stephen Mackinnon, Donald Milligan

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Support for Home Administration of Biological Therapy in Patients With Severe Asthma: BioCart©

    Support for Home Administration of Biological Therapy in Patients With Severe Asthma: BioCart© per Julio Delgado Romero, Marina Blanco–Aparicio, Carolina Cisneros Serrano, D. Díaz-Pérez, Raúl Ferrando Piqueres, Valentín López-Carrasco, Vicente Merino‐Bohórquez, Lorena Soto‐Retes, Javier Domínguez‐Ortega

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model

    Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model per Tycho Baumann, Julio Delgado, R. Santacruz, Alejandra Martínez‐Trillos, Cristina Royo, Alba Navarro, M. Pinyol, Marı́a Rozman, Arturo Pereira, Neus Villamor, Marta Aymerich, Cristina López, Ana Carrió, Emili Montserrat

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics

    IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics per Ferran Nadeu, Romina Royo, Guillem Clot, Martí Duran‐Ferrer, Alba Navarro, Silvia Martín, Junyan Lu, Thorsten Zenz, Tycho Baumann, Pedro Jares, Xosé S. Puente, José I. Martín‐Subero, Julio Delgado, Elı́as Campo

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    <i>MYD88</i>L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome

    <i>MYD88</i>L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome per Jordina Rovira, Kennosuke Karube, Alexandra Valera, Dolors Colomer, Anna Enjuanes, Luís Colomo, Alejandra Martínez‐Trillos, Eva Giné, Iván Dlouhy, Laura Magnano, Julio Delgado, Antonio Martı́nez, Neus Villamor, Elı́as Campo, Armando López‐Guillermo

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

    Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study per Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Ulrich Jäger

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC) per Pau Abrisqueta, Julio Delgado, Miguel Alcoceba, Ana Carla Oliveira, Javier Loscertales, José‐Ángel Hernández‐Rivas, Christelle Ferrà, Raúl Córdoba, Lucrecia Yáñez, Ángeles Medina, Cristina Motlló, Gloria Iacoboni, Guillermo Villacampa, Marcos González, Francesc Bosch

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials

    Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective mult... per José Luís Piñana, Rodrigo Martino, Jorge Gayoso, Anna Sureda, Javier de la Serna, José L. Díez‐Martín, Lourdes Vázquez, R. Arranz, José Francisco Tomás, Antònia Sampol, C. Solano, Julio Delgado, Jorge Sierra, D. Caballero

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)

    Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of... per Robert D Sandler, Rachel Tattersall, Hélène Schoemans, Raffaella Greco, Manuela Badoglio, Myriam Labopin, Tobias Alexander, К. И. Киргизов, Montserrat Rovira, Muhammad Saif, Riccardo Saccardi, Julio Delgado, Zinaida Perić, Christian Koenecke, Olaf Penack, Grzegorz Basak, John A. Snowden

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  18. 18
    Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia

    Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia per Gabriel Bretones, M. Alvarez, Javier R. Arango, David Rodrı́guez, Ferran Nadeu, Miguel A. Prado, Rafael Valdés‐Mas, Diana Puente, João A. Paulo, Julio Delgado, Neus Villamor, Armando López‐Guillermo, Daniel Finley, Steven P. Gygi, Elı́as Campo, Vı́ctor Quesada, Carlos López‐Otín

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

    Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era per Alfredo Rivas‐Delgado, Laura Magnano, Miriam Moreno‐Velázquez, Olga García, Ferran Nadeu, Pablo Mozas, Iván Dlouhy, Tycho Baumann, Jordina Rovira, Blanca González‐Farré, Antonio Martı́nez, Olga Balagué, Julio Delgado, Neus Villamor, Eva Giné, Elı́as Campo, Juan M. Sancho‐Cia, Armando López‐Guillermo

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

    Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia per Francesc Bosch, Pau Abrisqueta, Neus Villamor, María José Terol, Eva González‐Barca, Christelle Ferrà, Marcos González, Eugènia Abella, Julio Delgado, Félix Carbonell, José Antonio García Marco, Lourdes Escoda, Secundino Ferrer, Encarnación Monzó, Yolanda González, Cristina Estany, Isidro Jarque, Olga Salamero, Ana Muntañola, Emili Montserrat

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: